BioCryst reports influenza drug study results
Peramivir is an intravenously administered investigational anti-viral agent, which delivers high plasma concentrations to the sites of infection. The open-label, randomised, safety and virology Phase III study evaluated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.